Company Overview and News
Deep Sea Mooring (DSM) and Vryhof Anchors, both Vryhof businesses, have secured a contract to provide full-scale mooring and anchoring services to Australian energy company Cooper Energy. The announcement also sees Vryhof businesses secure contracts in Cooper's main target drilling area - offshore Victoria, Australia - for the first time.
As the oil and gas market braces for a rush in mergers and acquisitions, Australia’s recent forecast domestic gas shortage has done more than just raise concerns of an energy crisis, it also drew attention to a market ripe for takeover.
Good morning, ladies and gentlemen, and welcome to the Diamond Offshore Drilling Second Quarter 2017 Earnings Conference Call. At this time, all participants are in a listen-only mode. Later, we will have a question-and-answer session and instructions will be given at that time. As a reminder, this conference call is being recorded.
Energean Oil & Gas SA subsidiary Energean Israel expects the start of gas production from the Karish main development in 2020 after an estimated capital expenditure of $1.3-1.5 billion (OGJ Online, Jan. 13, 2017).
The Adelaide duo of Beach Energy Ltd. and Cooper Energy Ltd. has successfully completed a five-well campaign in Callawonga oil field in PPL220 in the South Australian Cooper-Eromanga basins.
A combine led by Cairn Energy Ltd. has completed drilling of an appraisal well in SNE oil field offshore Senegal. The group recording strong flow rates in the SNE-6 well from the upper reservoirs.
An area of mutual interest encompassing 1,100 sq miles of the Delaware basin will be imaged this year by the Coyanosa Survey, a joint venture of FairfieldNodal and Schlumberger Ltd. The project’s first phase will cover 306 sq miles of 3D seismic in Ward, Reeves, and Pecos counties in Texas. The survey will identify, “multiple reservoirs and drilling hazards that exist in the area,” said Maurice Nessim, president, WesternGeco, Schlumberger.
2018-04-25 - Asif
Overview Genocea Biosciences is a biopharmaceutical company that discovers and develops novel cancer vaccines. The company use its proprietary discovery platform, ATLAS, to recall a patient’s pre-existing CD4+ and CD8+ T cell immune responses to their tumor to identify antigens for inclusion in vaccines that are designed to act through T cell (or cellular) immune responses. The company believe that using ATLAS to identify antigens for inclusion in cancer vaccines could lead to more immunogenic and efficacious cancer vaccines. In September 2017, the company announced a strategic shift to immuno-oncology and a focus on the development of neoantigen cancer vaccines. Currently, all of its research programs and product candidates in active development are at the preclinical stage. The company's most advanced program is its preclinical immuno-oncology program, GEN-009, a neoantigen cancer vaccine. The GEN-009 program uses ATLAS to identify patient neoantigens, or newly formed anti...
2018-04-25 - Asif
Overview Amazon.com opened its virtual doors on the World Wide Web in July 1995. The company seek to be Earth’s most customer-centric company. Amazon is guided by four principles: customer obsession rather than competitor focus, passion for invention, commitment to operational excellence, and long-term thinking. In each of its segments, the company serve its primary customer sets, consisting of consumers, sellers, developers, enterprises, and content creators. In addition, the company provide services, such as advertising services and co-branded credit card agreements. Amazon has organized its operations into three segments: North America, International, and Amazon Web Services (“AWS”). These segments reflect the way the Company evaluates its business performance and manages its operations. Additional information on its operating segments and its net sales is contained in Item 8 of Part II, “Financial Statements and Supplementary Data—Note 11—Segment Information.” The compan...
2018-04-23 - Asif
Overview Lipocine is a specialty pharmaceutical company focused on applying its oral drug delivery technology for the development of pharmaceutical products in the area of men’s and women’s health. The company's proprietary delivery technologies are designed to improve patient compliance and safety through orally available treatment options. The company's primary development programs are based on oral delivery solutions for poorly bioavailable drugs. Lipocine has a portfolio of proprietary product candidates designed to produce favorable pharmacokinetic (“PK”) characteristics and facilitate lower dosing requirements, bypass first-pass metabolism in certain cases, reduce side effects, and eliminate gastrointestinal interactions that limit bioavailability. The company's lead product candidate, TLANDO™, is an oral testosterone replacement therapy (“TRT”) and is currently under review by the United States Food and Drug Administration (“FDA”) with a Prescription Drug User Fee Act (“...